u/peak_area_pete

UV sees things that absorb UV. water does not. salts mostly do not. that one sentence explains most of the confusion in this community.

put a deliberately ambiguous shoulder in it. that is where the variance lives and a clean trace will just show everyone agreeing.

this is the table i should have put in the post. adding it to the wiki version.

this is the ideal outcome and thank you for taking it well. the software prints whatever you configure it to print and defaults are not judgements.

yes, and it is the same failure — trusting the display over the process.

Yes — log what happened rather than what you intended. My retrospective entries were quietly wrong every time.

the largest-single-impurity number is criminally under-reported. a 98.6% that is one 1.2% impurity is a different molecule situation to a 98.6% spread across eight small peaks.

Gave the same trace to two people I trust and got two integrations about a point apart. That was the most educational afternoon I have had here.

Trace posted without axis labels — asked for a relabelled version rather than removing it.

UV response is not uniform across species. At 214nm you are looking at the peptide bond, which is why it is the working wavelength for this class; at 280nm you only see tryptophan, tyrosine and phenylalanine.

Left up. The integration disagreement in this thread is the most useful thing on the board this week.

Retitled: the original claimed a comparison the post does not actually make.

What this compound is actually being developed for, since the boards treat it as a weight-loss molecule with a footnote.

It is a dual GLP-1 and glucagon receptor agonist, and the glucagon arm links to hepatic fat and energy expenditure. The headline programme is metabolic liver disease, with endpoints scored on biopsy rather than on a scale.

That matters for how the data should be read. A histological response rate in a biopsy-confirmed population answers a very different question from a mean weight change in an obesity trial, and quoting one in place of the other — which happens in nearly every thread here — is not a comparison.

What does the tolerability table say at that dose?

That template is elaborate enough that you will stop using it by week ten. Mine was.

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

Left up. The integration disagreement in this thread is the most useful thing on the board this week.

Retitled: the original claimed a comparison the post does not actually make.

Yes — quoting their own policy bulletin back at them is far more effective than arguing in general terms.

Trace posted without axis labels — asked for a relabelled version rather than removing it.

Not convinced. That is a formulary exclusion rather than a prior authorisation denial, and the route to challenge it is different.

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

the column has a history and it shows in the peak shape

Correction: that is a formulary exclusion, not a prior authorisation denial. Different form, different route, different deadline.

That advice is jurisdiction-specific and this board spans several. Say where you are.

Correction: that is a formulary exclusion, not a prior authorisation denial. Different form, different route, different deadline.

A peer-to-peer conversation puts the prescribing clinician in front of a reviewing clinician. It bypasses the correspondence cycle entirely and is often the fastest available route.

phase 2 in liver disease is a different evidence question from weight

Trace posted without axis labels — asked for a relabelled version rather than removing it.

Retitled to name the endpoint.

This is the framing the board needs. It is a hepatic programme first.

Left up. The integration disagreement in this thread is the most useful thing on the board this week.

That advice is jurisdiction-specific and this board spans several. Say where you are.

Method questions stay here; supplier claims go to c/vendorvetting with a document attached.

glucagon agonism and energy expenditure is the mechanistic thread

That criterion is from the previous plan year. The current bulletin has different wording.

Cosigning the wavelength point. Half the disagreements in this board are two people looking at different detectors.

Trace posted without axis labels — asked for a relabelled version rather than removing it.